SG11201906943VA - Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use - Google Patents
Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic useInfo
- Publication number
- SG11201906943VA SG11201906943VA SG11201906943VA SG11201906943VA SG11201906943VA SG 11201906943V A SG11201906943V A SG 11201906943VA SG 11201906943V A SG11201906943V A SG 11201906943VA SG 11201906943V A SG11201906943V A SG 11201906943VA SG 11201906943V A SG11201906943V A SG 11201906943VA
- Authority
- SG
- Singapore
- Prior art keywords
- peptide
- international
- elastin
- human
- lock
- Prior art date
Links
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000003993 interaction Effects 0.000 title abstract 3
- 101000851054 Homo sapiens Elastin Proteins 0.000 title abstract 2
- 102000054289 human ELN Human genes 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 108010064033 elastin-binding proteins Proteins 0.000 abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 108010075254 C-Peptide Proteins 0.000 abstract 3
- 102000016942 Elastin Human genes 0.000 abstract 2
- 108010014258 Elastin Proteins 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229920002549 elastin Polymers 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- RLCSROTYKMPBDL-USJZOSNVSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RLCSROTYKMPBDL-USJZOSNVSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 235000012054 meals Nutrition 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108010011876 valyl-glycyl-valyl-alanyl-prolyl-glycine Proteins 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17154889 | 2017-02-06 | ||
| PCT/EP2018/052822 WO2018141969A1 (fr) | 2017-02-06 | 2018-02-05 | Modulateurs peptidiques de l'interaction entre le peptide c humain et le récepteur d'élastine humaine à usage thérapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906943VA true SG11201906943VA (en) | 2019-08-27 |
Family
ID=57995050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906943VA SG11201906943VA (en) | 2017-02-06 | 2018-02-05 | Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use |
| SG11201906939XA SG11201906939XA (en) | 2017-02-06 | 2018-02-05 | Interaction between c-peptides and elastin receptor, a model for understanding vascular disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906939XA SG11201906939XA (en) | 2017-02-06 | 2018-02-05 | Interaction between c-peptides and elastin receptor, a model for understanding vascular disease |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20200087374A1 (fr) |
| EP (3) | EP4421088A2 (fr) |
| JP (2) | JP7438757B2 (fr) |
| AU (2) | AU2018215245B2 (fr) |
| CA (2) | CA3051293A1 (fr) |
| ES (1) | ES2927977T3 (fr) |
| SG (2) | SG11201906943VA (fr) |
| WO (2) | WO2018141970A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6982395B2 (ja) * | 2017-03-16 | 2021-12-17 | 三洋化成工業株式会社 | インターロイキン１０の産生量増加剤 |
| WO2019104391A1 (fr) * | 2017-12-01 | 2019-06-06 | St Vincent's Institute Of Medical Research | Thérapie du diabète de type 1 |
| WO2021040526A1 (fr) * | 2019-08-30 | 2021-03-04 | Biotempt B.V. | Peptide q-er |
| CN111704653B (zh) * | 2020-06-08 | 2023-10-03 | 深圳市图微安创科技开发有限公司 | 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途 |
| CN112345770A (zh) * | 2020-11-06 | 2021-02-09 | 苏州大学附属第一医院 | 弹性蛋白降解肽作为腹膜透析患者血管钙化标志物的应用 |
| JP2024537696A (ja) * | 2021-10-01 | 2024-10-16 | ケアジェン カンパニー，リミテッド | 脱毛防止又は発毛促進活性を有するペプチドとその用途 |
| EP4412633A1 (fr) * | 2021-10-05 | 2024-08-14 | Biotempt B.V. | Contrôle angiogénique, de préférence combiné à une régulation glycémique |
| WO2024014953A1 (fr) | 2022-07-12 | 2024-01-18 | Resiliun B.V. | Traitement d'affections caractérisées par une hypoglycémie associée à l'hyperinsulinémie |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE520392C2 (sv) | 1996-09-27 | 2003-07-01 | Creative Peptides Sweden Ab C | Specifika peptider för behandling av diabetes mellitus |
| US6734289B2 (en) * | 2001-03-29 | 2004-05-11 | The University Of Chicago | Gastrokines and derived peptides including inhibitors |
| GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
| GB0323979D0 (en) * | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
| GB0412174D0 (en) * | 2004-06-01 | 2004-06-30 | Creative Peptides Sweden Ab | Degradation-resistant analogues of pro-insulin c-peptide |
| WO2008118387A2 (fr) * | 2007-03-23 | 2008-10-02 | Wayne State University | Modulateurs de la libération d'atp par les érythrocytes |
| EP2626704B1 (fr) * | 2012-02-08 | 2015-11-18 | Mehmet Ali Soylemez | Diagnostic du diabète pancréatique chez les patients avec les valeurs normales de leucocytes sanguins en utilisant la procalcitonine |
| BR112014025189B1 (pt) * | 2012-04-12 | 2020-04-07 | Brahms Gmbh | métodos de predizer o risco de adquirir um evento adverso e de orientação de tratamento com antibióticos em um paciente com insuficiência cardíaca crônica estável |
| JP6430962B2 (ja) * | 2013-01-08 | 2018-11-28 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心血管系疾患発症リスクの予測的マーカーとしての成長ホルモンの空腹時レベル |
| WO2014145836A1 (fr) * | 2013-03-15 | 2014-09-18 | Health Diagnostic Laboratory, Inc. | Procédé de génération d'un score d'indice de déficience en mbl en vue de prédire un risque de cardiodiabète |
| CN104371003A (zh) * | 2013-08-15 | 2015-02-25 | 上海市第一人民医院 | 预防和治疗炎症的小分子多肽及其应用 |
| WO2015140317A1 (fr) * | 2014-03-21 | 2015-09-24 | Sanofi | Nouveaux marqueurs pour l'évaluation du risque de développement de trouble cardiovasculaire |
-
2018
- 2018-02-05 JP JP2019563680A patent/JP7438757B2/ja active Active
- 2018-02-05 SG SG11201906943VA patent/SG11201906943VA/en unknown
- 2018-02-05 AU AU2018215245A patent/AU2018215245B2/en active Active
- 2018-02-05 WO PCT/EP2018/052824 patent/WO2018141970A1/fr active Application Filing
- 2018-02-05 SG SG11201906939XA patent/SG11201906939XA/en unknown
- 2018-02-05 US US16/483,717 patent/US20200087374A1/en not_active Abandoned
- 2018-02-05 US US16/483,317 patent/US20220009988A1/en not_active Abandoned
- 2018-02-05 CA CA3051293A patent/CA3051293A1/fr active Pending
- 2018-02-05 AU AU2018216033A patent/AU2018216033B2/en active Active
- 2018-02-05 ES ES18705843T patent/ES2927977T3/es active Active
- 2018-02-05 EP EP24170487.3A patent/EP4421088A2/fr active Pending
- 2018-02-05 CA CA3049738A patent/CA3049738A1/fr active Pending
- 2018-02-05 WO PCT/EP2018/052822 patent/WO2018141969A1/fr unknown
- 2018-02-05 EP EP18705844.1A patent/EP3577462B1/fr active Active
- 2018-02-05 EP EP18705843.3A patent/EP3570875B1/fr active Active
-
2023
- 2023-05-01 US US18/310,188 patent/US20240027431A1/en active Pending
-
2024
- 2024-02-13 JP JP2024019238A patent/JP2024056838A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7438757B2 (ja) | 2024-02-27 |
| EP3577462C0 (fr) | 2024-04-17 |
| JP2020507623A (ja) | 2020-03-12 |
| AU2018215245A1 (en) | 2019-07-25 |
| CA3049738A1 (fr) | 2018-08-09 |
| SG11201906939XA (en) | 2019-08-27 |
| US20240027431A1 (en) | 2024-01-25 |
| WO2018141970A1 (fr) | 2018-08-09 |
| JP2024056838A (ja) | 2024-04-23 |
| ES2927977T3 (es) | 2022-11-14 |
| EP3570875A1 (fr) | 2019-11-27 |
| CA3051293A1 (fr) | 2018-08-09 |
| EP4421088A2 (fr) | 2024-08-28 |
| EP3577462B1 (fr) | 2024-04-17 |
| AU2018216033A1 (en) | 2019-08-15 |
| AU2018215245B2 (en) | 2024-07-11 |
| US20200087374A1 (en) | 2020-03-19 |
| WO2018141969A1 (fr) | 2018-08-09 |
| EP3577462A1 (fr) | 2019-12-11 |
| AU2018216033B2 (en) | 2021-10-07 |
| EP3570875B1 (fr) | 2022-07-06 |
| US20220009988A1 (en) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906943VA (en) | Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201900200XA (en) | Tgfb antibodies, methods, and uses | |
| SG11201809381XA (en) | Polynucleotides encoding interleukin-12 (il12) and uses thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201903282TA (en) | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201810687SA (en) | Serum albumin-binding fibronectin type iii domains | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201906509WA (en) | Lipocalin muteins with binding affinity for lag-3 | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof |